查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933349

全球細菌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Bacterial Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 170 Pages | 商品交期: 請詢問到貨日

價格

細菌疫苗市場成長因素

受細菌感染發生率上升、疫苗接種計劃擴大以及各地區政府大力支持等因素的推動，全球細菌疫苗市場正經歷強勁增長。根據 Fortune Business Insights 的數據顯示，2025 年全球細菌疫苗市場規模為 296.8 億美元。預計到 2026 年將達到 325.2 億美元，到 2034 年將達到 813.5 億美元，預測期內複合年增長率 (CAGR) 為 12.14%。北美地區憑藉較高的疫苗接種率和先進的醫療基礎設施，在 2025 年佔市場主導地位，市佔率達 40.97%。

細菌疫苗旨在透過刺激免疫系統識別並中和細菌病原體來保護個體免受細菌感染。這些疫苗在預防危及生命的疾病方面發揮關鍵作用，例如肺炎球菌感染、腦膜炎雙球菌感染、白喉、破傷風和百日咳。人們對醫療保健和疫苗接種益處的認識不斷提高，並持續推動全球對細菌疫苗的需求。

市場動態

市場驅動因素

全球細菌性疾病發生率的上升是市場成長的主要驅動因素。快速的城市化、人口密度的增加以及國際旅行和移民都促進了細菌感染的傳播，從而增加了對有效疫苗接種策略的需求。此外，公眾疾病預防意識的提高和國家疫苗接種計劃的擴大顯著提高了疫苗接種覆蓋率，從而支持了市場擴張。

市場限制因子

監管障礙是細菌疫苗市場面臨的主要限制因素。 疫苗研發需要漫長的臨床試驗、嚴格的監管合規性以及大量的資金投入，研發週期通常長達 10 至 15 年。各國監管要求的差異進一步加劇了全球審批和商業化的複雜性，限制了市場成長。

市場機會

日益嚴重的抗菌素抗藥性 (AMR) 為細菌疫苗市場帶來了巨大的機會。接種疫苗可以減少對抗生素的依賴，並有助於遏制抗藥性細菌的出現。在全球抗生素抗藥性蔓延的背景下，細菌疫苗作為一種預防措施正日益受到重視，從而推動了疫苗研發投資和資金的增加。

市場挑戰

細菌的生物複雜性為疫苗研發帶來了重大挑戰。與病毒不同，細菌擁有多種抗原，這使得識別能夠產生持久保護性免疫反應的標靶變得困難。這種複雜性增加了研發成本和風險，可能會限制市場成長。

細菌疫苗市場趨勢

影響市場走向的顯著趨勢之一是耐熱細菌疫苗的研發。這類疫苗可在較寬的溫度範圍內保持穩定，從而降低對冷鏈物流的依賴。耐熱疫苗提供了一種經濟高效且實用的解決方案，尤其適用於基礎設施有限的新興經濟體。預計在預測期內，冷藏疫苗研發投入的增加和正在進行的臨床試驗將進一步鞏固這一趨勢。

細分市場分析

依類型劃分，重組/結合/次單位疫苗憑藉其高效性、長期保護作用和可擴展的生產工藝，在2024年佔市場主導地位。滅活疫苗憑藉其安全性和對免疫功能低下患者的適用性，佔第二大市場。

依給藥途徑劃分，注射劑疫苗在2024年佔市場主導地位。這是因為大多數細菌疫苗都是注射劑，能夠快速產生免疫反應。由於口服疫苗給藥方便且成本優勢明顯，預計其成長速度將更快。

依年齡組別劃分，受出生率上升和兒童疫苗接種計劃擴大的推動，兒童疫苗在2024年佔最大佔有率。由於成人細菌感染的盛行率不斷上升，成人疫苗也持續佔較大佔有率。

依適應症劃分，肺炎鏈球菌感染疫苗在2024年佔市場主導地位，這得益於強有力的疫苗接種建議和日益加重的疾病負擔。白喉-破傷風-百日咳疫苗也對市場成長做出了顯著貢獻。

依分銷管道劃分，並受聯合國兒童基金會和全球疫苗免疫聯盟等組織的大規模採購和疫苗接種活動的支持，政府供應商在2024年佔市場主導地位。

區域展望

預計北美地區在2025年將創造165.5億美元的收入，這得益於強有力的疫苗接種計劃和高額的醫療保健支出。

歐洲地區預計將保持穩定成長，這得益於其集中採購體系和較高的疫苗接種覆蓋率。

亞太地區是成長最快的地區，這主要得益於龐大的人口基數、政府的疫苗接種計劃以及印度和中國等國家強大的疫苗生產能力。

拉丁美洲以及中東和非洲地區預計將保持穩定成長，這得益於國際資金的增加以及耐熱疫苗和口服疫苗的普及。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家/地區主要疾病的發生率/盛行率（2025 年）
  • 主要公司產品線分析
  • 細菌疫苗的技術進步
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購、業務合作等等。

第五章 全球細菌疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 重組/結合/次單位疫苗
    • 滅活​​疫苗
    • 減毒活疫苗
    • 類毒素疫苗
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 注射劑
    • 口服
  • 市場分析、洞察與預測：依年齡組別劃分
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依適應症劃分
    • 腦膜炎雙球菌感染
    • 肺炎鏈球菌感染
    • 白喉、破傷風和百日咳 (DTP)
    • 其他
  • 市場分析、洞察與預測：依分銷管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美細菌疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲市場分析細菌疫苗市場：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區細菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲細菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東與非洲細菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Sanofi
    • GSK plc.
    • Merck &Co., Inc.
    • Bharat Biotech
    • Pfizer Inc.
    • Emergent BioSolutions, Inc.
    • Serum Institute of india Pvt. Ltd.
    • BIO-MED
Product Code: FBI113652

Growth Factors of bacterial vaccines Market

The global bacterial vaccines market is witnessing robust growth, supported by the rising incidence of bacterial infections, increasing immunization programs, and strong government support across regions. According to Fortune Business Insights, the global bacterial vaccines market was valued at USD 29.68 billion in 2025. The market is projected to reach USD 32.52 billion in 2026 and further expand to USD 81.35 billion by 2034, registering a CAGR of 12.14% during the forecast period. In 2025, North America dominated the market with a share of 40.97%, driven by high vaccine adoption rates and advanced healthcare infrastructure.

Bacterial vaccines are designed to protect individuals against bacterial infections by stimulating the immune system to recognize and neutralize bacterial pathogens. These vaccines play a critical role in preventing life-threatening diseases such as pneumococcal disease, meningococcal disease, diphtheria, tetanus, and pertussis. Rising awareness regarding preventive healthcare and vaccination benefits continues to accelerate global demand for bacterial vaccines.

Market Dynamics

Market Drivers

The growing incidence of bacterial diseases worldwide is a major driver of market growth. Rapid urbanization, increased population density, global travel, and migration have contributed to the spread of bacterial infections, increasing the need for effective immunization strategies. In addition, rising public awareness regarding disease prevention and expanding national immunization programs have significantly increased vaccine uptake, supporting market expansion.

Market Restraints

Regulatory hurdles present a notable restraint in the bacterial vaccines market. Vaccine development involves lengthy clinical trials, strict regulatory compliance, and high capital investment, often extending development timelines up to 10-15 years. Variations in regulatory requirements across countries further complicate global approvals and commercialization, limiting the pace of market growth.

Market Opportunities

The growing threat of antimicrobial resistance (AMR) presents a major opportunity for the bacterial vaccines market. Vaccination reduces reliance on antibiotics, thereby helping to control the emergence of drug-resistant bacterial strains. As antibiotic resistance continues to rise globally, bacterial vaccines are increasingly recognized as a preventive solution, encouraging higher investments and funding support for vaccine development.

Market Challenges

The biological complexity of bacteria poses a significant challenge for vaccine development. Unlike viruses, bacteria possess diverse antigens, making it difficult to identify targets that can generate long-lasting and protective immune responses. This complexity increases research costs and development risks, potentially limiting market growth.

Bacterial Vaccines Market Trends

A prominent trend shaping the market is the development of thermostable bacterial vaccines. These vaccines remain stable across a wide temperature range, reducing dependence on cold-chain logistics. Thermostable vaccines offer a cost-effective and practical solution, especially for emerging economies with limited infrastructure. Increasing R&D investments and ongoing clinical trials for fridge-free vaccines are expected to strengthen this trend during the forecast period.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by its high efficacy, long-term protection, and scalable manufacturing processes. The inactivated vaccines segment held the second-largest share, supported by their safety profile and suitability for immunocompromised individuals.

By route of administration, the parenteral segment led the market in 2024, as most bacterial vaccines are injectable and provide rapid immune responses. The oral segment is expected to grow at a faster pace due to ease of administration and cost advantages.

By age group, the pediatric segment accounted for the largest share in 2024, driven by rising birth rates and expanded childhood immunization programs. The adult segment also maintained a substantial share due to increasing prevalence of bacterial infections among adults.

By indication, the pneumococcal disease segment dominated the market in 2024, supported by strong vaccination recommendations and rising disease burden. Diphtheria, tetanus, and pertussis vaccines also contributed significantly to market growth.

By distribution channel, government suppliers dominated the market in 2024, supported by large-scale procurement and vaccination campaigns led by organizations such as UNICEF and GAVI.

Regional Outlook

North America generated USD 16.55 billion in revenue in 2025, supported by strong vaccination programs and high healthcare spending.

Europe is expected to witness steady growth due to centralized procurement systems and high immunization coverage.

Asia Pacific is the fastest-growing region, driven by large population bases, government immunization initiatives, and strong vaccine manufacturing capabilities in countries such as India and China.

Latin America and the Middle East & Africa are projected to grow steadily, supported by increasing international funding and adoption of thermostable and oral vaccines.

Competitive Landscape

The bacterial vaccines market is highly consolidated, with Sanofi, GSK plc., and Merck & Co., Inc. holding a significant share. These companies focus on strong R&D pipelines, global manufacturing capabilities, and strategic collaborations. Other notable players include Bharat Biotech, Pfizer Inc., Emergent BioSolutions, and Serum Institute of India, which continue to expand their product portfolios to strengthen market presence.

Conclusion

The global bacterial vaccines market is set for substantial growth during the forecast period, driven by increasing bacterial disease burden, rising immunization coverage, and growing awareness of preventive healthcare. With the market valued at USD 29.68 billion in 2025, projected to reach USD 32.52 billion in 2026 and expand to USD 81.35 billion by 2034, continuous advancements in vaccine technology, including thermostable formulations and expanded pediatric immunization programs, are expected to shape the future landscape. Despite challenges related to regulatory complexity and bacterial diversity, sustained government support and innovation-driven strategies are anticipated to support long-term market expansion.

Segmentation By Type

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Age Group

  • Pediatrics
  • Adults

By Indication

  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the Bacterial Vaccines
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Live Attenuated
    • 5.1.4. Toxoid
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatrics
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Meningococcal Disease
    • 5.4.2. Pneumococcal Disease
    • 5.4.3. Diphtheria/Tetanus/Pertussis
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Live Attenuated
    • 6.1.4. Toxoid
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatrics
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Meningococcal Disease
    • 6.4.2. Pneumococcal Disease
    • 6.4.3. Diphtheria/Tetanus/Pertussis
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Live Attenuated
    • 7.1.4. Toxoid
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatrics
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Meningococcal Disease
    • 7.4.2. Pneumococcal Disease
    • 7.4.3. Diphtheria/Tetanus/Pertussis
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Live Attenuated
    • 8.1.4. Toxoid
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatrics
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Meningococcal Disease
    • 8.4.2. Pneumococcal Disease
    • 8.4.3. Diphtheria/Tetanus/Pertussis
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Live Attenuated
    • 9.1.4. Toxoid
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatrics
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Meningococcal Disease
    • 9.4.2. Pneumococcal Disease
    • 9.4.3. Diphtheria/Tetanus/Pertussis
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Live Attenuated
    • 10.1.4. Toxoid
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatrics
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Meningococcal Disease
    • 10.4.2. Pneumococcal Disease
    • 10.4.3. Diphtheria/Tetanus/Pertussis
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Sanofi
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. GSK plc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Bharat Biotech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Emergent BioSolutions, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Serum Institute of india Pvt. Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. BIO-MED
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 5: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 10: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 16: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 17: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 22: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 32: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 34: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 35: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Bacterial Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Bacterial Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Bacterial Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Bacterial Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 6: Global Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Bacterial Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 9: North America Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 10: North America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 14: North America Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 15: North America Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 16: North America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Bacterial Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Bacterial Vaccines Market Value Share (%), By Country, 2025
  • Figure 20: Europe Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 21: Europe Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 22: Europe Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 28: Europe Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Asia Pacific Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 34: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 39: Asia Pacific Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 40: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 45: Latin America Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 46: Latin America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Latin America Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 52: Latin America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 57: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Type, 2025
  • Figure 58: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 63: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Indication, 2025
  • Figure 64: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Bacterial Vaccines Market Share (%), By Company, 2025